Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Public ClinicalTrials.gov record NCT05588609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers
Study identification
- NCT ID
- NCT05588609
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Partner Therapeutics, Inc.
- Industry
- Enrollment
- 13 participants
Conditions and interventions
Interventions
- Abiraterone acetate tablets Drug
- Afatinib Oral Tablet Drug
- Enzalutamide Pill Drug
- MCLA-128 Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2022
- Primary completion
- Jul 2, 2025
- Completion
- Jul 2, 2025
- Last update posted
- Apr 26, 2026
2022 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Oncology Institute of Hope & Innovation | Whittier | California | 90603 | — |
| Florida Cancer Specialists | Lake Mary | Florida | 32746 | — |
| The Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| TriHealth Cancer Institute | Cincinnati | Ohio | 45220 | — |
| University Hospitals - Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05588609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05588609 live on ClinicalTrials.gov.